Kyntra Bio, Inc. cash flow to debt ratio of -5.58% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Kyntra Bio, Inc.'s free cash flow has increased -96.52% from $-138.26M last year to $-4.81M, signaling increasing performance

Kyntra Bio, Inc.'s debt to equity ratio is -0.44, signaling that the company spent its equity and risk bankruptcy.

Kyntra Bio, Inc.'s debt to equity ratio is -0.44, signaling that the company spent its equity and risk bankruptcy.

Kyntra Bio, Inc. has a net cash position, so leverage is healthy.

Kyntra Bio, Inc.'s interest coverage ratio is -5.03, which means that the company struggles to meet interest obligations, signaling financial risk.

Kyntra Bio, Inc.'s profit margin has increased (-1.47K%) in the last year from -160.63% to 2.20K%, signaling increasing performance

Kyntra Bio, Inc.'s short-term assets of $99.07M exceed its short-term liabilities of $29.24M

Kyntra Bio, Inc.'s return on assets of 149.24% is higher than the 5.00% threshold, indicating efficient asset utilization

Kyntra Bio, Inc.'s return on equity of -234.28%, is lower than 15.00%, indicating bad performance

Kyntra Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Kyntra Bio, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Kyntra Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Kyntra Bio, Inc. has negative free cash flow, indicating cash burn

Kyntra Bio, Inc.'s yearly earnings has increased -485.57% since last year from $-47.58M to $183.45M, signaling increasing performance

Kyntra Bio, Inc.'s yearly revenue has decreased 78.26% since last year from $29.62M to $6.44M, signaling decreasing performance

ROIC -55.02% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Kyntra Bio, Inc.'s 3-year revenue CAGR of -64.23% is negative, indicating declining revenue over the past 3 years

Kyntra Bio, Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

Kyntra Bio, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Kyntra Bio, Inc. has insufficient data to evaluate this check.

Kyntra Bio, Inc. has an earnings yield of 580.04%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Kyntra Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Kyntra Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Kyntra Bio, Inc. is overvalued relative to its fair value price of -54.32 based on Earnings Fair Value model

Kyntra Bio, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Kyntra Bio, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Kyntra Bio, Inc. has a price-to-sales ratio of 3.79x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue